Latest news with #Hu-mAtrIxTM
Yahoo
12-03-2025
- Business
- Yahoo
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies
- Élancé Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but preserve and even increase muscle and lean mass- Élancé Therapeutics will leverage HCAb-based bispecific antibody technology to advance these next-generation therapies- Élancé will refine and expand Hu-mAtrIxTM AI platform to empower multiple bispecific antibody discovery programs CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 12, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced the launch of Élancé Therapeutics ("Élancé"). Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, Élancé aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle preservation and long-term efficacy. Obesity affects nearly one billion people worldwide and is associated with serious health complications, yet current treatments remain inadequate for many patients. Despite recent advancements, challenges such as limited efficacy, lean mass loss, and post-treatment weight regain highlight the need for novel approaches that offer sustained benefits and better clinical outcome. To address these gaps, Élancé is building a pipeline of bispecific antibody programs designed to improve weight loss outcomes while preserving lean muscle mass. By integrating dual-targeting strategies with enhanced safety profiles, these therapies have the potential to complement and expand upon existing treatment options, including various agonists of GLP-1 receptor, GIP receptor, and GCG receptor. Élancé's pipeline includes multiple bispecific antibody programs in preclinical development, each designed to offer innovative mechanisms of action, including targeted hormone modulation and enhanced metabolic regulation. These programs are supported by Harbour BioMed's validated HCAb-based bispecific antibody discovery platform, which has been successfully applied across multiple therapeutic areas. In addition, Élancé will refine and expand Nona Biosciences' Hu-mAtrIxTM AI platform to support bispecific antibody discovery, with AI applications guiding antibody sequence discovery, enrichment, optimization, bispecific geometry design, and developability/immunogenicity/pharmacokinetics (PK) assessments, as well as patient biomarker studies. "Our bispecific antibody programs enable a new paradigm in obesity treatment by targeting multiple pathways in a precise and effective manner," said Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed. "With a focus on optimizing weight loss efficacy, preserving lean muscle mass, and improving long-term outcomes, we believe our approach has the potential to redefine obesity therapeutics." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions. The proprietary antibody technology platform Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to About Élancé Therapeutics Élancé Therapeutics is a biotechnology company developing next-generation biologics for obesity treatment. Incubated by Harbour BioMed, Élancé Therapeutics leverages advanced bispecific antibody technology to address key challenges in obesity management, including limited efficacy, lean mass loss, and post-treatment weight regain. With a pipeline of innovative bispecific antibody programs targeting novel pathways, the company aims to provide effective and sustainable treatment solutions that complement existing obesity therapies. View original content to download multimedia: SOURCE Harbour BioMed Sign in to access your portfolio
Associated Press
07-03-2025
- Business
- Associated Press
Nona Biosciences Integrates Cutting-Edge AI Technology to Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas
CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from 'Idea to IND' (I to ITM), today announced to unveil its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM. This new platform, powered by advanced artificial intelligence, integrates seamlessly with the company's proprietary Harbour Mice® technology platform, aiming to accelerate antibody discovery across multiple key therapeutic areas, including neurodegenerative and metabolic diseases, and more. Nona's cutting-edge technology platform enables a fully integrated antibody discovery from protein design and single cell-based antibody screening to next-generation sequencing, antibody modeling and engineering. The Hu-mAtrIxTM platform is designed to significantly shorten discovery timelines, increase efficiency, and improve the overall success rate of antibody drug development by introducing a creative paradigm of antibody discovery empowered by AI and automation technologies. Hu-mAtrIxTM offers integrated solutions to identify the best antibodies with high efficiency. It allows the exploration of large libraries of human antibody sequences to identify the best sequence with the desired target specificity and binding affinity. Furthermore, it can predict the key antibody properties such as stability, manufacturability and immunogenicity, mitigating development risks in the early stages of discovery. In addition, Nona Biosciences is developing a new AI model to expand its core technology platform HCAb PlusTM. The new model leverages the unique capabilities of its HCAb Harbour Mice®, the industry's leading fully human heavy-chain-only transgenic mouse platform, and the proprietary HCAb dataset, to push the boundaries of antibody discovery, enabling the identification of rare, highly specific antibodies with greater precision and efficiency. 'We are excited to introduce the Hu-mAtrIxTM platform, an assistant tool to complement and enhance our existing antibody discovery solutions,' said Dr. Jingsong Wang, Chairman of Nona Biosciences. 'By combining our proprietary Harbour Mice® with the power of AI, we are addressing key challenges in drug discovery—reducing time-to-market, increasing the likelihood of successful candidates, and providing our partners with more targeted therapeutic options.' About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:
